By Yuichi Iwaki, M.D., Ph.D.
B.T. Slingby, director of global partner solutions at Eisai, noted a trend in Japan's pharma market: proactive globalization, in which U.S. pharma companies could consider some advice regarding partnerships.
By Rob Wright, Chief Editor, Life Science Leader
In 2000, I sat in a hotel ballroom at a national meeting for my new employer, Organon — a little-known European pharmaceutical company based in the Netherlands. The company’s U.S. president, Hans Vemer, M.D., Ph.D., compared success in the pharmaceutical industry to playing tennis; in order to be successful, you need to play where the ball is.